title: Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy.
abstract: The nitric oxide (NO) signaling pathway is integrally involved in visual processing and changes in the NO pathway are measurable in eyes of diabetic patients. The small peptide adrenomedullin (ADM) can activate a signaling pathway to increase the enzyme activity of neuronal nitric oxide synthase (nNOS). ADM levels are elevated in eyes of diabetic patients and therefore, ADM may play a role in the pathology of diabetic retinopathy. The goal of this research was to test the effects of inhibiting the ADM/NO signaling pathway in early diabetic retinopathy. Inhibition of this pathway decreased NO production in high-glucose retinal cultures. Treating diabetic mice with the PKC β inhibitor ruboxistaurin for 5 weeks lowered ADM mRNA levels and ADM-like immunoreactivity and preserved retinal function as assessed by electroretinography. The results of this study indicate that inhibiting the ADM/NO signaling pathway prevents neuronal pathology and functional losses in early diabetic retinopathy.
authors: Department of Biology, Boston University, Boston, MA USA.
authors: Jan J
authors: JJ
authors: Blom
authors: Thomas J
authors: TJ
authors: Giove
authors: Tara L
authors: TL
authors: Favazza
authors: James D
authors: JD
authors: Akula
authors: William D
authors: WD
authors: Eldred
keywords: Adrenomedullin; Diabetic retinopathy; Nitric oxide; PKC β; Ruboxistaurin